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BACKGROUND: Genome-wide association studies have identified 
chromosome 14q32 as a locus for coronary artery disease. The disease-
associated variants fall in a hitherto uncharacterized gene called HHIPL1 
(hedgehog interacting protein-like 1), which encodes a sequence 
homolog of an antagonist of hedgehog signaling. The function of HHIPL1 
and its role in atherosclerosis are unknown.
METHODS: HHIPL1 cellular localization, interaction with sonic 
hedgehog (SHH), and influence on hedgehog signaling were tested. 
HHIPL1 expression was measured in coronary artery disease–relevant 
human cells, and protein localization was assessed in wild-type and 
Apoe−/− (apolipoprotein E deficient) mice. Human aortic smooth muscle 
cell phenotypes and hedgehog signaling were investigated after gene 
knockdown. Hhipl1−/− mice were generated and aortic smooth muscle 
cells collected for phenotypic analysis and assessment of hedgehog 
signaling activity. Hhipl1−/− mice were bred onto both the Apoe−/− and 
Ldlr−/− (low-density lipoprotein receptor deficient) knockout strains, and 
the extent of atherosclerosis was quantified after 12 weeks of high-fat 
diet. Cellular composition and collagen content of aortic plaques were 
assessed by immunohistochemistry.
RESULTS: In vitro analyses revealed that HHIPL1 is a secreted protein that 
interacts with SHH and increases hedgehog signaling activity. HHIPL1 
expression was detected in human smooth muscle cells and in smooth 
muscle within atherosclerotic plaques of Apoe−/− mice. The expression of 
Hhipl1 increased with disease progression in aortic roots of Apoe−/− mice. 
Proliferation and migration were reduced in Hhipl1 knockout mouse 
and HHIPL1 knockdown aortic smooth muscle cells, and hedgehog 
signaling was decreased in HHIPL1-deficient cells. Hhipl1 knockout caused 
a reduction of >50% in atherosclerosis burden on both Apoe−/− and 
Ldlr−/− knockout backgrounds, and lesions were characterized by reduced 
smooth muscle cell content.
CONCLUSIONS: HHIPL1 is a secreted proatherogenic protein that 
enhances hedgehog signaling and regulates smooth muscle cell 
proliferation and migration. Inhibition of HHIPL1 protein function might 
offer a novel therapeutic strategy for coronary artery disease.
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Over the past decade, genome-wide association studies (GWAS) have identified a large num-ber of loci that associate with increased risk 
of coronary artery disease (CAD).1–4 Remarkably, only 
approximately one-third are also associated with con-
ventional cardiovascular risk factors,2 and many loci 
contain genes that have not previously been implicated 
in cardiovascular pathophysiology.3 Investigation of the 
function of these genes and identifying the pathways 
through which the genetic variants exert their effects 
might facilitate the development of novel therapeutic 
strategies for the treatment of CAD.
The CAD-associated variants at the 14q32 locus fall 
in HHIPL1 (Hedgehog interacting protein-like 1), a gene 
of unknown function that encodes a paralog of the 
hedgehog signaling regulator HHIP (hedgehog interact-
ing protein).5,6 
The mammalian hedgehog proteins (SHH [sonic 
hedgehog], DHH [desert hedgehog], and IHH [Indian 
hedgehog]) are secreted molecules that exert a con-
centration- and time-dependent effect on target cells.7 
Signal transduction is initiated upon binding of a hedge-
hog ligand to the canonical receptor PTCH1 and PTCH2 
(Patched 1 and 2),8 which leads to disinhibition of SMO 
(Smoothened). SMO triggers a complex signaling cascade 
that regulates the activation of the GLI (glioma-associat-
ed oncogene homolog 1) family zinc finger transcription 
factors (GLI1, GLI2, and GLI3).7 GLI activators induce the 
transcription of target genes primarily involved in cell pro-
liferation, cell survival, and cell fate specification. Among 
those genes are several components of the hedgehog 
pathway itself, including PTCH and GLI.9,10 HHIP modu-
lates hedgehog signaling activity by binding and inhibit-
ing the action of hedgehog proteins.5,6,11,12
Hedgehog signaling is indispensable for normal em-
bryonic development7 and plays critical roles in the main-
tenance of adult progenitor and stem cell populations and 
in tissue repair after injury.13 In the cardiovascular system, 
hedgehog signaling is essential for early vascular develop-
ment,14–16 vascular remodeling in the yolk sac,17,18 arterial-
venous identity,19,20 development and maintenance of 
the coronary vasculature,20,21 and vessel maturation.22 In 
adults, hedgehog signaling is involved in the maintenance 
of adult vasculature and for ischemia-induced neovascu-
larization, including after myocardial infarction.23–27 The 
role of hedgehog signaling in atherosclerosis is less well 
defined. Expression of hedgehog pathway components 
has been detected in plaques, and inhibition of hedge-
hog signaling using an antibody that blocks binding of all 
3 hedgehog proteins to PTCH1 increased atherosclerosis 
in Apoe−/− (apolipoprotein E deficient) mice.28,29
Here, we report the first experimental investigation 
of HHIPL1 and present evidence that it is a secreted pro-
atherogenic protein that regulates smooth muscle cell 
proliferation and migration.
METHODS
Upon reasonable request, the data, analytical methods, and 
study materials will be made available to other researchers for 
the purposes of reproducing the results. Extended methods 
are provided in the online-only Data Supplement.
Reagents and Cell Lines
Plasmids were prepared by the Protein Expression Laboratory 
(PROTEX) cloning service at the University of Leicester. 
Immunoprecipitation was performed using GFP-Trap beads 
(Chromotek). Anti-FLAG (F3165, Sigma), anti-GFP (MA5-
15256, Thermo Fisher Scientific), anti-GLI1 (AF3455, R&D 
Systems), and anti-β-actin (11355703, Thermo Fisher 
Scientific) were used for immunoblotting. HEK293 cells 
were purchased from American Type Culture Collection, and 
human aortic smooth muscle cells (AoSMCs) were purchased 
from Invitrogen and Thermo Fisher Scientific; peripheral 
blood mononuclear cells and macrophages were prepared as 
described previously.30 Coronary artery endothelial cells were 
purchased from PromoCell. SHH-LIGHT2 cells were the kind 
gift of Professor P.A. Beachy, Stanford University.
SHH Reporter Assays
Analysis of hedgehog signaling activity was performed with 
SHH-LIGHT2 cells, a clonal NIH-3T3 cell line stably express-
ing a Gli-dependent firefly luciferase and constitutive Renilla 
reporters, as previously described31 with minor modifications. 
SHH-LIGHT2 cells were seeded in 96-well plates at a density 
of 4000 cells per well in 200 µL of DMEM with 10% FBS. 
Once confluent, cells were cultured for a further 12 to 24 
hours before treatment with conditioned media. Conditioned 
medium was prepared by transfecting HEK293 cells with 
Clinical Perspective
What Is New?
• This is the first investigation of HHIPL1 (hedge-
hog interacting protein-like 1), a candidate gene 
at the chromosome 14q32 coronary artery disease 
locus identified through genome-wide association 
studies.
• We show that HHIPL1 is a secreted protein that 
interacts with sonic hedgehog and is a positive 
regulator of hedgehog signaling.
• In murine models, HHIPL1 deficiency attenuates 
the development of atherosclerosis by reducing 
smooth muscle cell proliferation and migration.
What Are the Clinical Implications?
• Our study supports HHIPL1 as the causal gene at 
the 14q32 coronary artery disease locus.
• HHIPL1 is a promising therapeutic target that 
affects a pathogenic mechanism not addressed by 
current treatments for coronary artery disease.
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SHH-GFP, HHIP-FLAG, HHIPL1-GFP, or GFP control plasmid. 
Twenty-four hours after transfection, medium was changed to 
DMEM with 0.5% FBS and collected after a further 24 hours 
for treatment of SHH-LIGHT2 cells. Firefly luciferase and Renilla 
were measured 24 hours after treatment using the Dual-Glo 
Luciferase assay system (Promega) and read on a Novostar 
plate reader (BMG LabTech). The hedgehog signaling activity 
of mouse AoSMCs was measured by co-culturing wild-type 
or Hhipl1−/− cells with SHH-LIGHT2 cells. Three wild-type and 
3 Hhipl−/− AoSMCs were used for experiments. Cells were 
seeded at 5000 SHH-LIGHT2 and 2500 AoSMCS per well in 
96-well plates in replicates of 3 to 6. When cells reached con-
fluence, medium was changed to DMEM containing 0.5% 
FBS. Luciferase activity was measured 24 hours later.
Cellular Assays
Proliferation was determined by incubating with PrestoBlue 
(Thermo Fisher Scientific) and measuring fluorescence emis-
sion or by counting cells. Cell migration was measured using 
a wound-healing assay. Apoptosis was measured by staining 
cells with FITC Annexin V (Biolegend) and measured with a 
Beckman Coulter Gallios flow cytometer.
Generation of Mouse Models
All work involving animals was approved by the local animal 
ethics committee and performed according to ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) guidelines and 
under United Kingdom Home Office Project Licence (60/4332). 
All mice were housed in a specific pathogen-free facility in an 
individually ventilated caging system and were group housed 
wherever possible, and the health status was checked rou-
tinely. Other than weight gain associated with high-fat diet, 
no mice demonstrated any adverse effects. A genetically 
altered mouse strain was generated from embryonic stem 
cells (Hhipl1tm1a(KOMP)Wtsi), purchased from the Knockout Mouse 
Project (KOMP), by the Gene Editing and Archiving Service 
(GenEAS) in the University of Leicester Division of Biological 
Services. All work reported here was conducted on mice car-
rying the knockout first allele (Hhipl1tm1a(KOMP)Wtsi), which is sub-
sequently referred to as Hhipl1−/−.
Analysis of Atherosclerosis
The Hhipl1−/− strain was backcrossed onto a C57BL6/J back-
ground for 6 generations before being intercrossed with 
Apoe−/− and Ldlr−/− (low-density lipoprotein receptor deficient) 
mice to generate Hhipl1−/−;Apoe−/− and Hhipl1−/−;Ldlr−/− mice 
and control littermates. Because of genotype requirements, 
mice could not be randomized into groups. Experiments were 
powered for en face analysis of atherosclerosis as the primary 
objective. The intercrossed mice were fed a high-fat Western 
diet (TestDiet 5TJN: fat 40%, carbohydrate 44%, protein 16%, 
cholesterol 0.15%) for 12 weeks from 6 weeks of age. The 
aortic roots and thoracic aortas were collected and processed. 
For en face analysis, after overnight fixation in 4% PFA, the 
thoracic aorta was opened longitudinally and stained with 
60% Oil Red O (Sigma-Aldrich) and imaged with a DM2500 
Leica microscope. The lipid-stained area was quantified with 
LAS V 4.0 software by a researcher blinded to genotype and 
is presented as a percentage of total aortic area. For aortic 
roots, lesion area was measured on Oil Red O–stained sec-
tions from frozen embedded hearts. Ninety 10-μm sections 
were collected to obtain 900 μm of aortic length from the 
appearance of the aortic sinus (identified by the appearance of 
aortic cusps), which was deemed point zero. Quantification of 
lesion area was performed across 9 sections (100 µm between 
sections). For en face analysis, the data are presented as aver-
age lesion area normalized to total aorta area. For aortic root 
analysis, the data are presented as area.
Atherosclerotic Lesion Compositional 
Analysis
Smooth muscle cells were stained with anti-α-smooth muscle 
actin (SMA; ab5694, Abcam), which detects smooth muscle 
α-actin 2 (ACTA2), and macrophages were stained using 
macrophages/monocytes antibody (MOMA-2; MCA519G, 
Bio-Rad). Slides were fixed in cold acetone at −20°C and air 
dried, and endogenous peroxidase activity was blocked in 
0.3% H2O2/methanol. Nonspecific binding was reduced by 
incubation in 2.5% goat serum (Vector Laboratories) before 
primary antibody incubation at 4°C in a humidified chamber 
overnight. Slides were incubated with ImmPRESS HRP anti-
rabbit (Vector Laboratories, MP-7451) or anti-rat IgG per-
oxidase (Vector Laboratories, MP-7444), and staining was 
visualized using DAB and counterstained in hematoxylin (Gill 
No. 2, Sigma-Aldrich). Images were acquired with a DM2500 
Leica microscope. Positively stained areas of each aorta were 
measured with ImageJ by a researcher blinded to genotype. 
The data are presented as the average of positively stained 
lesion areas (9 serial sections) normalized by total lesion area. 
For collagen and lipid core quantification, sections were 
stained with Masson’s trichrome (Sigma-Aldrich) according to 
the manufacturer’s instructions.
Hhipl1 Staining
Serial frozen aortic root sections from Apoe−/− and wild-
type mice were stained by immunohistochemistry with anti-
HHIPL1 (HPA052767; Atlas Antibodies), MOMA-2, and SMA 
(ab32575; Abcam) antibodies using the same methodology 
as before. Immunofluorescence was performed on paraf-
fin-embedded aortic root sections from Apoe−/− mice using 
anti-HHIPL1 antibody and Cy3-conjugated mouse mono-
clonal anti–α-SMA (1:200 C6198, Sigma-Aldrich) antibod-
ies. Sections were treated with antigen unmasking solution 
(H-3301, Vector Laboratories). Alexa Fluor 488–labeled goat 
anti-mouse secondary antibody (Thermo Fisher) was used 
to detect anti-HHIPL1 antibody localization. Images were 
acquired with a DM2500 Leica fluorescent microscope. Dual 
staining was quantified across 3 sections using ImageJ.
Statistical Analysis
Results are presented as mean±SD unless stated otherwise. 
We conducted 2-sample unpaired Student t tests for vari-
ables that were normally distributed and compared between 
2 groups. If the variable was not normally distributed, we con-
ducted a Mann–Whitney test. For the SHH reporter, Hhipl1 
expression, and human AoSMC migration data, we used the 
ANOVA approach to compare >2 groups. For mouse and 
human AoSMC proliferation data, the ANOVA model also 
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incorporated time and the 2-way interaction effect of group 
and time. We modeled the body weight of each mouse (mea-
sured separately at weekly intervals throughout the study) 
using a linear mixed model, incorporating genotype and time 
as fixed effects and mouse as a random effect. We assessed 
all models for underlying assumptions using appropriate plots 
and statistics. When multiple comparisons of grouping vari-
ables were conducted, we adjusted estimated probabilities by 
the Tukey method to account for multiple comparisons. All 
statistical tests were 2-sided with a type 1 error rate (P value) 
of 0.05 to determine statistical significance. All statistical anal-
yses were performed with GraphPad Prism 7.00 (GraphPad 
Software Inc.) and R software version 3.5 (R Core Team, 2018).
RESULTS
HHIPL1 Is a Secreted Positive Regulator 
of SHH
HHIPL1 encodes a predicted secreted protein consisting 
of an N-terminal signal peptide followed by a span of 550 
amino acids that shares ≈50% identity to the hedgehog 
interacting region of HHIP and a C-terminal scavenger 
receptor cysteine-rich domain. We assessed the localiza-
tion of the HHIPL1 protein by expressing C-terminally 
FLAG GFP-tagged HHIPL1 expression constructs (HHIPL1-
FLAG and HHIPL1-GFP) in HEK293 cells. We detected 
HHIPL1-FLAG by Western blotting in both HEK293 cell 
lysates and in conditioned media precipitated with tri-
chloroacetic acid (Figure 1A). No HHIPL1-GFP was seen 
at the cell surface, which suggests that HHIPL1 is not 
associated with the cell membrane (Figure 1B and 1C).
Next, we investigated whether HHIPL1 interacts with 
SHH, the best characterized ligand of the hedgehog 
pathway. HEK293 cells were cotransfected by electro-
poration with HHIPL1-FLAG and SHH-GFP plasmids or 
empty vector controls followed by immunoprecipitation 
with GFP-Trap beads. Both HHIPL1-FLAG and SHH-GFP 
fusion proteins were detected in the immunoprecipi-
tated samples, which indicates that HHIPL1 and SHH 
interact (Figure 1D).
To assess whether HHIPL1 modulates SHH signal-
ing, we performed reporter assays using SHH-LIGHT2 
cells.30 HHIPL1-GFP in conditioned medium significantly 
increased Gli-luciferase activity compared with SHH-
GFP alone (P<0.001; Figure 1E), which suggests HHIPL1 
acts as a positive regulator of SHH. HHIP-FLAG caused 
a nonsignificant reduction compared with SHH-GFP 
treatment (P=0.44).
HHIPL1 Is Expressed by Smooth Muscle 
Cells and Controls Cell Proliferation and 
Migration
We measured HHIPL1 in primary human AoSMCs, cor-
onary artery endothelial cells, peripheral blood mono-
nuclear cells, and macrophages and found the highest 
expression in AoSMCs (Figure  2A). In addition, the 
Human Protein Atlas identified high levels of HHIPL1 
protein in human smooth muscle cells and breast myo-
epithelial cells, as well as lower levels in cardiac and 
skeletal muscle myocytes.32
Figure 1. HHIPL1 is a secreted interactor of SHH. 
A, Representative Western blot of HEK293 cell lysates and conditioned media 
after transfection of HHIPL1-FLAG plasmid. B and C, Representative confocal im-
ages of HEK293 cells expressing HHIPL1-GFP (green) costained with DAPI (blue). 
Bars, 10 μm. D, Western blots, immunoblotted with anti-GFP and anti-FLAG an-
tibodies, after transfection of HEK293 cells with HHIPL1-FLAG, SHH-GFP, and im-
munoprecipitation with anti-GFP beads. E, Gli-luciferase activity in SHH-LIGHT2 
cells incubated with conditioned media from HEK293 cells transfected with SHH-
GFP, HHIPL1-GFP, or HHIP-FLAG or a mixture of SHH-GFP with HHIPL1-GFP or 
HHIPL-FLAG; n=4–5. GFP indicates green fluorescent protein; HHIPL1, hedgehog 
interacting protein-like 1; IP, immunoprecipitation; ns, nonsignificant; and SHH, 
sonic hedgehog. Error bars represent mean±SD. **P≤0.01, ***P≤0.001.
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Figure 2. HHIPL1 regulates human AoSMC migration and proliferation. 
A, HHIPL1 mRNA expression in human aortic smooth muscle cells (AoSMC), coronary artery endothelial cells (CAEC), peripheral blood mononuclear cells (PBMC), 
and macrophages (MP) relative to 36B4. B, HHIPL1 mRNA expression relative to RPLP0 in AoSMCs 24 to 72 hours after transfection. C, Migration rate of rate of 
human AoSMCs after siRNA transfection (left; n=3). Representative images of wound-healing assay (right). D, Number of AoSMCs over 72 hours after siRNA 
knockdown. E, Proportion of apoptotic cells 48 hours after knockdown. F, GLI1 and PTCH1 expression relative to RPLP0 48 hours after siRNA knockdown. G, Rep-
resentative Western blot of GLI1 after siRNA knockdown. β-actin was used as a loading control. AoSMC indicates aortic smooth muscle cell; HHIPL1, hedgehog 
interacting protein-like 1; NTC, nontargeting control siRNA; and siRNA, small interfering RNA.
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We used small interfering RNA (siRNA) knockdown 
to investigate the cellular consequences of HHIPL1 
deficiency in human AoSMCs. We used 2 siRNAs to 
reduce HHIPL1 expression and achieved knockdown 
efficiencies between 70% and 95% compared with 
a nontargeting control siRNA (Figure 2B). Knockdown 
was retained over a period of 72 hours. We performed 
a scratch assay to assess the effect of HHIPL1 deficien-
cy on human AoSMC migration and found that the 
migration rate of HHIPL1 knockdown AoSMCs was 
lower than nontargeting control siRNA transfected 
cells (siRNA1 P<0.001, siRNA2 P<0.001; Figure  2C). 
We assessed the proliferation of HHIPL1 knockdown 
cells using a fluorescent cell viability assay and ob-
served a reduction in cell number in HHIPL1 knock-
down cells compared with controls (siRNA1 P=0.02, 
siRNA2 P=0.03 at 72 hours; Figure  2D). We detect-
ed no difference in apoptosis between control and 
HHIPL1 knockdown cells (Figure 2E).
GLI1 Expression Is Reduced in HHIPL1-
Deficient AoSMCs
Hedgehog signaling activates gene expression of path-
way members including GLI1 and PTCH1. We measured 
the expression of both genes after HHIPL1 knockdown 
in human AoSMCs and detected a significant reduction 
in GLI1 expression (siRNA1 P=0.041, siRNA2 P=0.0002; 
Figure  2F). We confirmed the reduction in GLI1 pro-
tein expression by Western blotting (Figure  2G). We 
did not detect a difference in PTCH1 expression. We 
also assessed PTCH2 expression, but this was below the 
threshold for quantification.
Hhipl1 Is Present in Smooth Muscle Cells 
In Vivo, and Its Expression Increases in 
Atherosclerosis
We investigated the expression of Hhipl1 in a hyperlipid-
emic mouse atherosclerosis model. First, we performed 
immunohistochemical analysis to detect Hhipl1 protein 
in aortic root sections from 18-week-old Apoe−/− mice 
fed a high-fat Western diet. Hhipl1 expression most 
closely matched cells stained with the smooth muscle 
marker ACTA2, but not those stained with MOMA-2, 
which recognizes a mouse macrophage antigen (Fig-
ure 3A and Figure IA in the online-only Data Supple-
ment). We also detected Hhipl1 expression in aortic 
arches from wild-type mice (Figure IB in the online-only 
Data Supplement).
We performed immunofluorescence staining of 
plaques to confirm expression of Hhipl1 in smooth 
muscle cells (Figure 3B) and detected Hhipl1 expres-
sion in 93.7±2.6% of ACTA2-expressing cells (n=3 
cells). 
Next, we assessed Hhipl1 levels during atheroscle-
rosis progression by measuring its expression in RNA 
collected from the aortic arch of Apoe−/− mice between 
6 and 48 weeks of age. Hhipl1 expression increased 
by approximately 3-fold throughout the study (Fig-
ure  3C). Post hoc comparisons to the 6-week time 
point showed a significant increase in expression at 
32 (P=0.002), 40 (P<0.001), and 48 weeks (P<0.001). 
Hhipl1 expression did not change in the aortic arch of 
wild-type mice across the same time frame (Figure IC 
in the online-only Data Supplement), which indicates 
that the increase in expression was the result of disease 
rather than age.
Generation and Characterization of 
Hhipl1 Knockout Mice
We obtained mouse embryonic stem cells carrying the 
Hhipl1 tm1a knockout first allele, which consists of a 
reporter-tagged insertion into intron 1 of the Hhipl1 
gene (Figure IIA in the online-only Data Supplement) 
from the KOMP Repository and generated Hhipl1−/− 
mice. The gene trap is predicted to cause a truncated 
Hhipl1 protein of just 91 amino acids. We confirmed 
absence of Hhipl1 expression in Hhipl1−/− mice at the 
mRNA level by reverse-transcription polymerase chain 
reaction (Figure IIB in the online-only Data Supple-
ment). Hhipl1−/− mice were monitored for signs of sub-
viability and dysmorphology at all stages, but nothing 
of note was observed. Mice were born in the expected 
mendelian frequency, and there were no losses perina-
tally or postnatally. Animals were weighed weekly and 
showed no difference in weight compared with wild-
type littermates.
Hhipl1 Knockout AoSMCs Show Reduced 
Proliferation and Migration
We collected AoSMCs from knockout mice and wild-
type littermates to test the effect of Hhipl1 deficiency 
on cell phenotype. Migration (P=0.02; Figure 4A) and 
proliferation (Figure 4B; P<0.001 at 96 hours of culture) 
of Hhipl1−/− mouse AoSMCs was decreased compared 
with wild-type cells. We saw no difference in apoptosis 
between groups (Figure 4C).
Hhipl1 Knockout AoSMCs Have Reduced 
Hedgehog Signaling Activity
To investigate hedgehog signaling activity, we cultured 
wild-type and Hhipl1−/− mouse AoSMCs together with 
SHH-LIGHT2 cells and performed luciferase reporter as-
says. Gli-luciferase activity was significantly reduced in 
knockout cells (P=0.008; Figure 4D). Similar to our ex-
periments in human cells, we detected a reduction in 
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expression of the hedgehog target gene Gli1 at both 
the mRNA (P=0.02) and protein (Figure 4E and 4F) lev-
el. We did not detect a change in Ptch1 expression in 
Hhipl1−/− AoSMCs.
Hhipl1 Knockout Decreases 
Atherosclerosis in 2 Mouse Models
We investigated the effect of Hhipl1 knockout on 
atherosclerosis in both Apoe−/− and Ldlr−/− mice. Male 
double knockouts (Hhipl1−/−;Apoe−/− and Hhipl1−/−;
Ldlr−/−) were fed a Western diet for 12 weeks and 
compared with littermates that were wild type for 
Hhipl1 (Hhipl1+/+;Apoe−/− and Hhipl1+/+;Ldlr−/−). Ath-
erosclerosis was quantified in the aorta by en face 
analysis (n=18–19 per group) and in sections of the 
aortic root (n=6–10 per group). Hhipl1−/−;Ldlr−/− mice 
exhibited a reduction of 56% in lesion area (7.5%; 
95% CI, 6.3%–8.7%) compared with Hhipl1+/+;Ldlr−/− 
littermate controls (3.3%; 95% CI, 2.3%–4.4%) as 
measured by en face analysis (P=5×10−6; Figure  5A 
and 5B). In aortic roots, there was a 37% reduction in 
mean lesion area between Hhipl1+/+;Ldlr−/− (3.08×105 
µm2; 95% CI, 2.37×105 to 3.79×105 µm2) and Hh
ipl1−/−;Ldlr−/− (1.93×105 µm2; 95% CI, 1.25×105 to 
2.61×105 µm2) mice (P=0.013; Figure  5C and 5D). 
Similarly, Hhipl1−/−;Apoe−/− mice displayed a 53% re-
duction in lesion area (7.5%; 95% CI, 5.7%–9.2%) 
compared with Hhipl1+/+;Apoe−/− controls (3.5%; 
95% CI, 2.5%–4.4%) by en face analysis (P=0.0002; 
Figure  5E and 5F). Aortic roots from Hhipl1−/−;Ap
oe−/− mice showed a decrease of 33% in mean lesion 
area (3.84×105 µm2; 95% CI, 2.92×105 to 4.76×105 
µm2) versus (2.57×105 µm2; 95% CI, 1.97×105 to 
3.16×105 µm2) compared with controls (P=0.039; 
Figure 5G and 5H).
There was no difference in body weight, plasma 
lipid levels, or blood pressure between experimental 
Figure 3. Hhipl1 expression in atherosclerotic plaques. 
A, Representative immunohistochemical staining with anti–α smooth muscle actin antibody (SMA), anti-Hhipl1, and MOMA-2 in aortic root lesions from 18-week-
old Apoe−/− mice fed Western diet for 12 weeks. Bars, 500 μm (top) and 200 μm (bottom). B, Immunofluorescent staining of aortic root lesion with DAPI, SMA, 
and anti-Hhipl1. Bars, 100 μm. C, Hhipl1 mRNA expression relative to Rpl4 in the aortic arch of 6- to 48-week-old Apoe−/− mice. n=3–6 mice per time point. Error 
bars represent mean±SD. HHIPL1 indicates hedgehog interacting protein-like 1. *Post hoc comparisons with 6-week time point. **P≤0.01, ***P≤0.001.
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and control groups on either background (Figure IIIA 
through IIIF in the online-only Data Supplement).
Hhipl1 Knockout Reduces Smooth Muscle 
Cell Content in Mouse Atherosclerotic 
Plaques
We characterized the cellular and collagen composi-
tion of aortic root lesions from Hhipl1−/−;Ldlr−/− (Fig-
ure  6A through 6H) and Hhipl1−/−;Apoe−/− mice (Fig-
ure 7A through 7H) compared with Hhipl1 wild-type 
littermates. Image analysis for lesion component cover-
age (as a percentage of the total lesion area) revealed 
no difference in lipids or macrophages within plaques 
of Hhipl1−/−;Ldlr−/− mice compared with controls (Fig-
ure 6A through 6D). We detected a 46% reduction in 
cells stained for SMA in Hhipl1−/−;Ldlr−/− lesions (13.9%; 
95% CI, 9.7%–18.2%) compared with controls (25.6%; 
95% CI, 20.9%, 30.5%; P=0.004; Figure 6E and 6F), 
as well as a nonsignificant reduction in collagen con-
tent in Hhipl1−/−;Ldlr−/− (P=0.07; Figure 6G and 6H). We 
did detect a reduction in the lipid content of Hhipl1−/−; 
Figure 4. HHIPL1 regulates mouse AoSMC migration and proliferation. 
A, Migration rate of Hhipl1−/− and wild-type AoSMCs in a scratch wound assay over a period of 24 hours (n=4). Representative images are shown (right). B, 
Proliferation of Hhipl1−/− and wild-type AoSMCs over a period of 96 hours (n=4). *Significant post hoc comparisons at 72 and 96 hours. C, Proportion of apoptotic 
wild-type and Hhipl1−/− AoSMCs. D, Gli-luciferase activity in SHH-LIGHT2 cells co-cultured with either wild-type or Hhipl1−/− AoSMCs; n=4. E, Gli1 and Ptch1 mRNA 
expression relative to Rplp0 in wild-type and Hhipl1−/− AoSMCs; n=5. Error bars represent mean±SD. *P≤0.05, **P≤0.01, ***P≤0.001. F, Western blot showing 
Gli1 expression in wild-type and knockout cells. β-actin was used as a loading control. AoSMC indicates aortic smooth muscle cell; HHIPL1, hedgehog interacting 
protein-like 1; and SHH, sonic hedgehog.
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Apoe−/− plaques (28.5%; 95% CI, 26%–31%) com-
pared with controls (32.9%; 95% CI, 29.6%–36.2%; 
P=0.02; Figure 7A and 7B). The other components of 
Apoe−/− plaques showed similar differences to those 
observed on the Ldlr−/− background. There was no dif-
ference in macrophage staining (Figure 7C and 7D and 
a 47% reduction in SMA-positive staining in Hhipl1−/
−;Apoe−/− mice (15.3%; 95% CI, 9.3%–21.4%) com-
pared with controls (29.1%; 95% CI, 24.2%–33.9%; 
P=0.001; Figure 7E and 7F) and a nonsignificant de-
Figure 5. Hhipl1 deficiency reduces atherosclerosis in Hhipl1−/−;Apoe−/− and Hhipl1−/−;Ldlr−/− mice. 
A, Representative Oil Red O–stained (ORO) aortas from Hhipl1+/+;Ldlr−/− and Hhipl1−/−;Ldlr−/− mice. B, Quantification of atherosclerosis in aortas of mice of each 
genotype as a percentage of total aorta area (n=18 vs n=19). C, Representative microphotographs of ORO-stained aortic root sections from Hhipl1+/+;Ldlr−/− and 
Hhipl1−/−;Ldlr−/− mice. D, Aortic root lesion area (9 sections per mouse, n=6 per group). E, ORO-stained aortas from Hhipl1+/+;Apoe−/− and Hhipl1−/−;Apoe−/−mice. 
F, Quantification of atherosclerosis in the aortas of mice of each genotype (n=19 vs n=18). G, ORO-stained aortic roots from Hhipl1+/+;Apoe−/− and Hhipl1−/−;Ap
oe−/− mice. H, Aortic root lesion area (9 sections per mouse, n=10 vs n=6). Bars, 2 mm (A and E); bars, 200 μm (C and G). Error bars represent mean±CI. HHIPL1 
indicates hedgehog interacting protein-like 1. *P≤0.05, ***P≤0.001.
D
ow
nloaded from
 http://ahajournals.org by on August 6, 2019
Aravani et al HHIPL1 Promotes Atherosclerosis
Circulation. 2019;140:500–513. DOI: 10.1161/CIRCULATIONAHA.119.041059 August 6, 2019 509
ORIGINAL RESEARCH 
ARTICLE
crease in collagen content (P=0.08; Figure  7G and 
7H). In addition to higher smooth muscle and collagen 
content,  plaques from Hhipl1−/− mice contained fewer 
cholesterol crystals and smaller lipid cores than con-
trols (Figure IVA through IVF in the online-only Data 
 Supplement).
DISCUSSION
A major challenge after GWAS is the identification of 
the causal gene and biological mechanisms underly-
ing each disease-associated locus. In this study, we 
investigated HHIPL1, an uncharacterized gene at the 
Figure 6. Hhipl1 deficiency reduces smooth muscle cell content in Hhipl1−/−;Ldlr−/− atherosclerotic lesions. 
Representative photomicrographs of atherosclerotic lesion components in Hhipl1+/+;Ldlr−/− and Hhipl1−/−;Ldlr−/− mice. A, Oil red O (ORO) staining for lipids; C, 
MOMA-2 staining for macrophages; E, anti–alpha smooth muscle actin (SMA) staining for smooth muscle cells; and (G) Masson trichrome for collagen. Bars, 200 
μm. The percentage content (average of 9 sections per animal) of (B) lipids, (D) macrophages, (F) smooth muscle cells, and (H) collagen (n=6 per group). Error bars 
represent mean±CI. HHIPL1 indicates hedgehog interacting protein-like 1. **P≤0.01.
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chromosome 14q32 CAD locus, and showed that it 
encodes a secreted SHH regulator that modulates ath-
erosclerosis-relevant smooth muscle cell phenotypes. 
We detected Hhipl1 expression in smooth muscle cells 
in atherosclerotic plaques, and its expression increased 
with disease progression. Most strikingly, knockout of 
Hhipl1 caused a substantial decrease in atherosclerosis 
on 2 different disease-prone backgrounds. Our data 
strongly support HHIPL1 as the causal gene at the 
14q32 CAD locus, link hedgehog signaling to athero-
sclerosis, and identify HHIPL1 as a potential target for 
therapeutic intervention.
Figure 7. Hhipl1 deficiency reduces smooth muscle cell content in Hhipl1−/−;Apoe−/− atherosclerotic lesions. 
Representative photomicrographs of atherosclerotic lesion components in Hhipl1+/+;Apoe−/− and Hhipl1−/−;Apoe−/− mice. A, Oil red O (ORO) staining for lipids; C, 
MOMA-2 staining for macrophages; E, anti-α smooth muscle actin (SMA) staining for smooth muscle cells; and G, Masson’s trichrome for collagen. Bars, 200 μm. 
Percentage coverage (average of 9 sections per animal) of (B) lipids, (D) macrophages, (F) smooth muscle cells (P=0.001), and (H) collagen (n=6–10 per group). 
Error bars represent mean±CI. HHIPL1 indicates hedgehog interacting protein-like 1. *P≤0.05, **P≤0.01. Bar, 200 μm.
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HHIPL1 is a paralog of the hedgehog signaling 
modulator HHIP,5 which interacts with each of the 3 
hedgehog ligands and inhibits signaling.6,11,12 HHIP is 
associated with lung function and chronic obstructive 
pulmonary disease in humans,33,34 and homozygous 
knockout of Hhip in mice causes lethality because of 
abnormal lung development,35 whereas heterozygous 
knockout animals develop emphysema.36 The function 
of HHIPL1 has not been investigated previously. Our 
data demonstrate that HHIPL1, like HHIP, is a secreted 
hedgehog interacting protein; however, unlike HHIP, 
HHIPL1 positively regulates hedgehog signaling. In ad-
dition to its homology with HHIP, HHIPL1 also contains 
a C-terminal scavenger receptor cysteine-rich domain. 
This domain is present in some of the scavenger re-
ceptors involved in lipid uptake in plaque development 
and is thought to be involved in protein-protein inter-
actions or ligand binding.37 Interestingly, cholesterol 
modification of the hedgehog proteins controls their 
distribution and receptor interactions.38 It is unclear 
whether the HHIPL1 scavenger receptor cysteine-rich 
domain is involved in the interaction with SHH via its 
cholesterol modification or some other mechanism, or 
whether it is required for a different hedgehog inde-
pendent function.
We detected HHIPL1 expression in AoSMCs and 
found that HHIPL1 protein localized to smooth muscle 
cells in atherosclerotic plaques. We also observed in-
creased Hhipl1 expression in the aortic roots of old-
er Apoe−/− mice. This is likely the result of increasing 
numbers of smooth muscle cells during atherosclerosis 
progression; however, we cannot exclude Hhipl1 ex-
pression also being affected by other factors related 
to plaque development. In normal adult arteries, the 
core hedgehog proteins are expressed between the ad-
ventitial and medial layers39 and after injury in smooth 
muscle cells in the media and intima.40,41 Although our 
results suggest that smooth muscle is the primary site 
of HHIPL1 function, we cannot exclude a role for Hhipl1 
in other atherosclerosis-relevant cell types, such as en-
dothelial or inflammatory cells. Conditional knockout 
of Hhipl1 in smooth muscle will help determine the cell 
specificity of its role in disease pathogenesis.
HHIPL1 deficiency reduced smooth muscle cell mi-
gration and proliferation in both human and mouse 
cells in vitro and reduced the proportion of smooth 
muscle cells in plaques in vivo. The hedgehog signal-
ing pathway is an established regulator of cell behav-
ior in multiple different systems,7,42,43 including smooth 
muscle cells.22,40,41,44–47 Hedgehog proteins can control 
these phenotypes through a variety of different mecha-
nisms, including directly acting as chemoattractants 
and by inducing signaling pathways involved in cell-
shape regulation and cell-cycle control. Although the 
exact mechanism of action of the hedgehog pathway 
on smooth muscle is unclear, SHH has been shown 
to mediate PDGFB (platelet-derived growth factor B)-
induced smooth muscle migration via ERK and PI3K sig-
naling,22 and hedgehog induction of neuropilins, which 
act as coreceptors of semaphorins and vascular endo-
thelial growth factor, has been linked to cell migration 
in the development of the aortic arch.48 Previous stud-
ies have also demonstrated that inhibition of hedgehog 
signaling induces smooth muscle cell apoptosis.45,47 We 
did not detect a difference in apoptosis in either our 
mouse or human experiments, which is possibly a re-
sult of the moderate reduction in hedgehog signaling 
caused by HHIPL1 deficiency compared with substantial 
loss of activity through pathway inhibition.
Our data clearly demonstrate a role for HHIPL1 
in atherosclerosis, with Hhipl1 knockout reducing 
plaque burden by >50% in 2 different hyperlipidemic 
mouse models. This reduction was not attributable to 
any changes in body weight, blood, or plasma lipids. 
Previously, Beckers et al29 used a monoclonal antibody 
that inhibits all 3 hedgehog proteins to investigate 
atherosclerosis in Apoe−/− mice and found that treat-
ed animals had larger, more advanced atherosclerotic 
plaques. The findings of that study are somewhat dif-
ferent from ours, because Apoe−/− mice treated with 
the inhibitory antibody did not gain weight and had 
reduced plasma cholesterol levels, and the increase 
in atherosclerosis was driven by an increase in mac-
rophage content, with no effect on smooth muscle. 
The efficiency of hedgehog inhibition in cells in the 
vessel wall was minimal, and the differences versus 
our study probably reflect the more general effects of 
global hedgehog inhibition. Nevertheless, both sets 
of data support a role for hedgehog signaling in ath-
erosclerosis, and further investigation of the hedge-
hog pathway in disease pathogenesis and as a po-
tential target for the treatment of CAD is warranted. 
Our data would suggest that inhibition of hedgehog 
signaling would reduce plaque development, and sev-
eral hedgehog pathway inhibitors exist, including the 
SMO antagonists vismodegib and sonidegib, which 
have US Food and Drug Administration approval for 
treatment of basal cell carcinoma.49,50 Directly target-
ing HHIPL1 might also represent a promising option 
for therapy.
Current drug therapies for reducing atherosclerosis 
are primarily targeted toward lipids. Our findings sug-
gest that targeting vascular smooth muscle cells may 
also be beneficial. Smooth muscle cell proliferation also 
plays a role in other vascular pathologies, including re-
stenosis after percutaneous coronary intervention and 
coronary graft occlusion. Whether HHIPL1 plays a role 
in these conditions and whether targeting it would be 
of benefit remains to be determined.
In conclusion, HHIPL1, whose locus is associated 
with CAD in humans, is a new positive regulator of 
hedgehog signaling that promotes atherosclerosis in 
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mice. Known hedgehog pathway modulators or novel 
therapeutic agents that directly target HHIPL1 are po-
tential new treatments for CAD.
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